Lilotomab
Lilotomab
Lilotomab (pronounced: li-lo-to-mab) is a monoclonal antibody designed for the treatment of non-Hodgkin lymphoma. It is a type of immunotherapy that targets the CD37 antigen on the surface of B cells.
Etymology
The name "Lilotomab" is derived from the Latin word "lilo" meaning "to bind", and "tomab" from the Greek "toma" meaning "a slice or piece". This refers to the antibody's ability to bind to a specific antigen (in this case, CD37) on the surface of a cell.
Usage
Lilotomab is used in combination with radiotherapy to treat patients with non-Hodgkin lymphoma. It works by binding to the CD37 antigen on the surface of B cells, which are a type of white blood cell that can become cancerous in non-Hodgkin lymphoma. Once bound, the antibody delivers a dose of radiation directly to the cancer cells, killing them and sparing healthy tissue.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Non-Hodgkin lymphoma: A type of cancer that originates in the lymphatic system, the body's disease-fighting network.
- Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
- CD37: A protein found on the surface of B cells.
- Radiotherapy: The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
External links
- Medical encyclopedia article on Lilotomab
- Wikipedia's article - Lilotomab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski